07 January 2008      
Volume `000 
Weekly movement as at 04 January 2007
JMH 400US$
Weekly movement as at 04 January 2007

Koh Brothers Group: Buys out Brothers (Holdings) 46.58% stake in construction JV for $18.97 million
DHL Express (Singapore): Buys SATS Courier Centre Two for $38 million
Chip Eng Seng: Inks 2 agreements to develop residential projects in Vietnam
JTC Corporation: Picks Australia-based Goodman Group to run its upcoming REIT
Allco: Raises $518 million for its Allco SIF Fund.


China Flexible Packaging Holdings: Exceeds RMB 1 billion in revenue sales for the year ending Oct 31 2007
Yangzijiang Shipbuilding Holdings: Wins 20 vessel shipbuilding contracts worth US$1.27 million
Capital Commercial Trust: Gets go ahead to convert Market Street Car Park into  $1.5 billion office tower
Sincere Watch: Director and controlling shareholder Tay Liam Wee takes 1% stake in Chronostar for $10.96 million


HOT Off The Press

Popular’s BookFest@Singapore 2007 Offered More Depth and Excitement for All Booklovers

One of Singapore’s largest and most successful book fairs returned this December with an extravaganza of great reads, promotions and exciting activities, be it for business, school or personal preferences. The BookFest@Singapore 2007 was staged at the Suntec Singapore International Convention and Exhibition Centre from 14 to 23 December. Admission was free. Occupying an area of 120,000 square feet with over 300 representative companies exhibiting, it showcased the latest and most comprehensive range of English and Chinese books, stationery and educational reads. Among the major attractions was an IT zone that unleashed the latest digital gadgets, tech gizmos, as well as assorted electronic and multimedia products with exclusive bargains. Booklovers were spoilt for choices at BookFest@Singapore 2007 as it featured a large variety of English and Chinese books of different genres, such as literature, humanities, education, science and technology, economics and travel.

The inaugural BookFest@Singapore in 2006 was a resounding success – the 10- day event attracted a turnout of more than 320,000 visitors. On top of that, Popular Holdings Limited also organized two very successful BookFests in Kuala Lumpur successively in May 2006 and May 2007. Encouraged by the overwhelming response, POPULAR has decided to continue with its mission to stage BookFest@Singapore year after year, and will strive to elevate the event towards the scale of international book fairs.

Participants were leading publishers, stationery and electronic peripheral distributors from China, Taiwan, Hong Kong, Malaysia, Singapore, United Kingdom and the United States. Themed “Read to Learn”, the 10-day extravaganza exhibited a wide range of titles with the objective of creating and stimulating a vibrant market for book retailing. Visitors can look forward to a plethora of enjoyable performances and activities, appearances by local artistes such as Singapore Idol champion Taufik Batisah, Singapore Idol finalists Olinda Cho and Jonathan Leong; renowned local and overseas authors; new book and product launches; educational seminars; health and wellness talks and lots more.

The mega event also offered unparalleled opportunities for exhibitors to market their products and services; serving as the perfect platform for publishers and distributors to network and establish links with one another. Held over two weekends of the December school holidays, BookFest@Singapore 2007 attracted more than 500,000 visitors over its 10- day run. BookFest@Singapore 2007 was officially opened by Dr. Lee Boon Yang, Minister of Information, Communications and the Arts on 13 December 2007. The grand ceremony was attended and supported by distinguished guests from Singapore and overseas.

Popular Holdings Limited, a leading Regional Education Group with strong operations in the Pan-Asian region, was founded in 1924 and listed on the Main Board of the Singapore Exchange in 1997. Popular has an integrated business model strategically built on its core competencies in publishing, retail & distribution and content creation. The Group has more than 40 subsidiaries and operations in Singapore, Malaysia, Hong Kong, Macau, Taiwan, China, United Kingdom and Canada.

CNA Incorporates Subsidiary In Oman

CNA Group Ltd (the Company) wishes to announce that it has formed a new subsidiary, CNA International – Oman L.L.C., under the laws of Oman (CNA-Oman), with an issued share capital of Omani Rials (RO) 250,000 (equivalent to approximately S$1,000,000).

CNA Integrated Technologies L.L.C. has an interest in approximately 51% of the share capital of CNA-Oman. The remaining shareholders are KBK Dubai Contracting L.L.C. (KBK), Sheikh Abdul Khaliq bin Amir bin Mansoor Al Rawas and Mohammad Hanif, holding interests of approximately 11%, 30% and 8% respectively of the share capital of CNA-Oman. CNA-Oman is expected to be engaged in the provision, design and implementation of integrated and automation systems for buildings and infrastructural facilities in Oman.

KBK is a company in which Bintai Kinden Corporation Berhad (“Bintai”), a company listed on the mainboard of Bursa Malaysia, has a 49% interest. Dato' Ang Liang Kim, an Executive Director of Bintai, is the brother of Mr Michael Ong Liang Huat, the President and Chief Executive Officer of the Company.

CNA Group Ltd. is an award-winning specialist in the provision, design, implementation and maintenance of advanced integrated control and automation systems and IT solutions that enable intelligent buildings and facilities. We are primarily focused in the turnkey development of integrated control and automation solutions, the provision of system maintenance and value-enhancement services and the sale of environmental control and engineering products.

Cambridge Industrial Trust To Acquire 21B Senoko Loop

Cambridge Industrial Trust Management Limited (the Manager), the Manager of Cambridge Industrial Trust (CIT), has identified 21B Senoko Loop (the Property) to be acquired by CIT at a purchase price of S$14,670,000. (known as the Acquisition).

In connection with the Acquisition, RBC Dexia Trust Services Singapore Limited, in its capacity as trustee of CIT (the Trustee), has entered into a conditional put and call option agreement (the Option Agreement) with Tellus Marine Engineering Pte Ltd (Tellus), to acquire the Property.

The Acquisition is expected to be financed by debt or alternative funding sources in line with the Manager’s capital management strategy in optimizing the funding of the Trust. The above Property will be accretive to CIT’s distributable income.

Cambridge Industrial Trust (CIT), listed on the Singapore Exchange on 25th July 2006, is Singapore's first independent industrial real estate investment trust (REIT), and a conduit for investors to Singapore's high growth industrial sector. The Trust invests in income-producing industrial properties and has an existing portfolio of 33 properties valued at $689.3 million. They range from logistics and warehousing properties to light industrial properties, all located across Singapore’s key industrial zones. This provides a secure and stable yield to Unitholders. The management team is anchored by experienced professionals with a breadth of expertise in fund, asset and property management sectors regionally as well as locally.

Natural Cool To Sell Property At 40 Defar Building Sungei Kadut Street 2 Singapore 729246

Natural Cool Holdings Limited (Company or Group) announced that its 51% subsidiary, J2 Pte. Ltd. (J2), has entered into an Option to Purchase (Option) with Luxx Newhouse Pte Ltd and/or its Nominee(s) (Purchaser) on 14 August 2007 for the sale of property at 40 Defar Building Sungei Kadut Street 2 Singapore 729246 (the Property) (the Proposed Sale) for a consideration of S$2.8 million (Sale Consideration) on the terms and conditions stated therein including obtaining the approval of the relevant governmental and statutory authorities. The Proposed Sale is completed on 28 December 2007 (Completion date).

The Sale Consideration of the of the Property was arrived at after arm’s length negotiations on a willing-buyer willing-seller basis after taking into account valuation report (Valuation Report) dated 1 August 2007 by GSK Global Pte Ltd and various commercial factors including comparing recent transacted prices in the vicinity. Based on the Valuation Report, the open market value of the Property is S$2.8 million. The Company and J2 are of the view that the Sale Consideration of S$2.8 million for the Property is fair and reasonable. The Sale Consideration will be by cash. The cash proceeds will be used for working capital to generate future growth.

The Proposed Sale is in line with the Group’s pursuit of asset-light strategy. It will also enable the Group to manage its capital effectively thereby strengthening its balance sheet.

Established in 1989 and listed on SGX-SESDAQ in May 2006, Natural Cool provides installation, maintenance, repair and replacement services for air-conditioning systems to the residential segment, both public and private; and commercial sectors, which include factories, offices, condominiums, schools and hospitals, in Singapore. In addition, the Group sells air conditioning components and tools used for the installation and servicing of air-conditioning business. The Group also manufactures and sells switchgears through mechanical and electrical (M&E) contractors to public and private property developments. Started in 2003, the Group’s switchgear division designs and manufactures switchgear products customized to meet specific requirements of its customers. In just 4 short years, it has expanded to become a vital part of the Group’s operations.

Biosensors Incorporates New India Subsidiary

Biosensors International Group, Ltd. (the Company) is pleased to announce that its wholly owned Singapore incorporated subsidiary, Biosensors Interventional Technologies Pte. Ltd. has incorporated a wholly owned subsidiary known as Biosensors Interventional Technologies (India) Private Limited (BIT India) in India.

The issued and paid up capital of BIT India is Rupees 500,000. The principal activities of BIT India are related to development, manufacture, assembly, and sale of medical devices/products.

The incorporation of BIT India is funded by internal resources and is not expected to have any material impact on the consolidated net tangible assets and earnings per share of the Company and the Group for the financial year ending 31 Mach 2008.

Biosensors International Group, Ltd. develops, manufactures and commercializes innovative medical devices used in interventional cardiology and critical care procedures. We are well positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional cardiovascular therapies. In June 2006, Biosensors was named one of 50 medical technology companies to be watched in Medical Device and Diagnostic Industry magazine's 50 companies to watch, which cited Biosensors' innovative biodegradable-polymer drug-eluting stents as one of the reasons for the Company to be watched.  


AEI Invests In New Extrusion Line To Replace Existing Extrusion Line

AEI Corporation Ltd. (the Company) wishes to announce that the Company will be investing in a new extrusion line in replacement of an existing extrusion line at an estimated cost of up to S$2,000,000.

The new extrusion line will comprise an 1800 US Tonne New Extrusion Press Machine equipped with Piercer Device and Aluminium Profile Handling System (excluding Puller and Stretcher) and peripheral equipment.

Delivery of the extrusion machine is expected to be in the second quarter of 2008. Installation of the extrusion line is targeted to be completed by the end of second quarter of 2008

AEI Corporation Ltd is principally engaged in the production of quality precision aluminium alloy extruded profiles. As an added service to our customers, we also provide anodising services in order to meet our customers' finishing requirements. Our business is categorised into two broad segments, namely, (a) electronics and precision engineering, and (b) construction and infrastructure building.

Meji Seika, A Leading Food And Pharmaceutical Company In Japan, Appoints C&O As Distributor In China For Its Best-Selling, New-Generation Antibiotics

C&O Pharmaceutical Technology (Holdings) Limited announced that Shantou Meiji Seika Kaisha Ltd has appointed C&O as distributor for the whole of China for its new-generation cephalosporin antibiotics “Meiact”. The distributorship agreement is for a 5-year term starting January 1, 2008.

Meiact is believed to be one of the best post-third generation oral cephalosporin antibiotics currently sold in the market. Launched in Japan by Meiji Seika in 1994, Meiact was the first foreign pharmaceutical product to obtain the Category 1 new drug certificate in China. Since its launch in 2001 in China, the product has established a solid foothold with target users. For the 12 months ended 31 March 2007, sales of Meiact in China were about US$4.7 million.

Prior to the appointment of C&O as distributor for the whole of China, Meiact was marketed by Meiji Seika’s sales team in China.

C & O Pharmaceutical Technology (Holdings) Limited (C&O) is an established and integrated pharmaceutical group in China. Our business model spans the entire value chain in the pharmaceutical industry, from research and development, to manufacturing, as well as marketing and distribution of C&O branded and third party pharmaceutical products via an extensive distribution network covering all parts of China.

ASL Marine Incorporates Jointly Controlled Entity

ASL Marine Holdings Ltd. (the Company or ASL Marine) wishes to announce that the Company's 50% owned jointly-controlled entity, ASL Energy Pte. Ltd. (ASL Energy) had on 26 December 2007 incorporated a wholly-owned subsidiary, Epsilon Shipping Pte. Ltd. (ESPL), in the Republic of Singapore.

ESPL has an issued and paid-up capital of S$2 and it will be principally involved in the chartering of marine vessels. ASL Energy’s investment in ESPL was funded through internal resources.

The investment in ESPL is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ending 30 June 2008. ASL Marine is a vertically-integrated marine company principally involved in Shipbuilding, Ship repair, Ship chartering and other marine related services, catering to customers mainly from Asia Pacific, South Asia, the Middle East and Europe. Headquartered and listed in Singapore, the Group owns and operates 3 shipyards in Singapore, Indonesia (Batam) and China (Guangdong), providing a comprehensive range of marine engineering services spanning myriad sectors/industries. Equipped with a fleet consisting mainly of tugs and barges, ASL Marine has also carved a niche in providing ship chartering services to the marine and offshore infrastructure sector. In May 2004, the Group successfully acquired the Tabang Coal Concession in Tabang, East Kalimantan which strategically ensures at least minimum utilisation of the Group's ship chartering fleet.

Darco Acquires Shares And Invesment Capital In Subsidiaries

Darco Engineering Pte Ltd (DEPL),a wholly-owned subsidiary of Darco Water Technologies, had acquired the shares and investment capital of the following companies from Darco Environmental Pte Ltd (DNV), another wholly-owned subsidiary of the Company:-

(1) 35,000,000 shares at NT$10 each (representing 100%) in the capital of Darco Engineering (Taiwan) Co., Ltd. for a consideration of NT$350,000,000 on 2 April 2007;
(2) entire investment capital of US$200,000 in Shanghai Challenge Environmental Engineering Co., Ltd for a consideration of US$60,000 on 22 June 2007;
(3) 64,997 shares at PHP100 each (representing 65%) in the capital of Darco Environmental (Philippines) Inc for a consideration of PHP6,499,700 on 21 December 2007; and
(4) 553,623 shares at US$1 each (representing 51%) in the capital of PT Darco Indonesia for a total consideration of US$553,623 on 25 June 2007.

The above acquisitions are in line with the Group’s initiatives to streamline operations as part of its ongoing restructuring exercise.

At Darco Water Technologies, we develop innovative engineering and knowledge-based solutions to provide for all water and wastewater requirements across various industries. Darco in cooperation with Kennicott completes the synergy in offering one of the most cutting edge water systems technological know-how and expertise with their combined experiences in the world of power, petrochemical, chemical and the energy sectors.

Rickmers Maritime Takes Delivery Of CMA CGM Onyx

Rickmers Trust Management Pte. Ltd. (RTM), trustee-manager of Rickmers Maritime, announced the early delivery of the 9th vessel (the Vessel) of its initial contracted fleet.

The 4,250 TEU containership was originally scheduled to deliver from Dalian Shipyard in China on 1 March 2008.

The Vessel, CMA CGM Onyx, will commence an 8-year fixed rate time charter to the world’s 3rd largest liner company, CMA-CGM.

Rickmers Maritime is a Singapore business trust formed with the objective of owning and operating containerships under long-term, fixed rate charters to container liner shipping companies. Rickmers Maritime’s asset portfolio, owned, contracted and committed, consists of a fleet of 23 containerships. The fleet comprises nine vessels in operation, ranging between 3,450 TEU and 5,060 TEU, and a further 13 contracted or committed vessels, ranging between 3,450 TEU and 13,100 TEU. Rickmers Maritime has also been granted a purchase option on one additional vessel, which is exercisable in January 2008.

Celestial Nutrifoods Sells Subsidiary

Celestial NutriFoods Limited (the Company) wishes to announce that the Company had entered into a share transfer agreement (the Share Transfer Agreement) with Mr. Zhang Li Qiang on 29 December 2007, to dispose its entire equity interest in its wholly-owned subsidiary, Mazuri Holdings Corp. (“Mazuri”). On the day of disposal, Mazuri held 100% interest in Celestial (Hong Kong) Nutriments Group Limited and 95% interest in Daqing Sun Moon Star Protein Co., Ltd.

The consideration of the disposal of Mazuri is RMB5,500,000 (the Purchase Consideration), which was agreed upon negotiation on a willing buyer and willing seller basis, taking into consideration that Mazuri and its subsidiaries were inactive companies. The Purchase Consideration will be satisfied partly in cash of RMB896,469.53 within sixty (60) days from the date of the Share Transfer Agreement and partly by the offset of an amount of RMB4,603,530.47 due by other subsidiaries of the Company to Mazuri and its subsidiaries.

The disposal of Mazuri is to rationalise the structure of the Company via divestment of non-core and inactive subsidiaries of the Company.

Established in 1997, we are today a leading manufacturer of soybean protein-based food products. Our manufacturing base is in Daqing City, Heilongjiang Province, where we operate well-equipped modern manufacturing facilities that are NQA-certified. Our manufacturing plants are located in Lindian, and the Soybean Zone Phase 1 where we occupy a land area of approximately 430,000 square meters. 


CEO's Walk The Talk

“..I remember that during our initial public offering last year, many asked if we had the experience to effectively execute commercialization of our BioMatrix product line. Frankly, we are confident of our capability but no amount of theory can help us prepare ourselves unless we have had the chance to exercise our skills in supplying DES, handling logistics management, and establishing the dedicated distribution network specific to DES sales.  This is similar to an athlete who must participate in smaller-scale competitions with the intent to hone his skills to gain competitive experience. A win in this competition is a bonus, but the biggest gains are the experience and the opportunity to test one's skills, minimise the imperfections, and be ready to win a competition in the Olympics.”

Lu Yoh-Chie CEO
Biosensors International Limited


Highlighted Company

Biosensors International Group, Ltd. develops, manufactures and commercializes innovative medical devices used in interventional cardiology and critical care procedures. We are well positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional cardiovascular therapies. In June 2006, Biosensors was named one of 50 medical technology companies to be watched in Medical Device and Diagnostic Industry magazine's 50 companies to watch, which cited Biosensors' innovative biodegradable-polymer drug-eluting stents as one of the reasons for the Company to be watched.

Through our high quality medical devices, we impact the lives we touch, and we are committed to continue investing in and developing pioneering medical technology, pharmacological research, and engineering new medical devices that will further benefit our patients. This will create the greatest possible patient outcomes, and provide value to our stakeholders including physicians, shareholders and employees.

Since 1990, Biosensors has been developing and marketing critical care catheter systems and related devices used during heart surgery and intensive care treatment and monitoring. In 2000, we entered the interventional cardiology market with our proprietary coronary stent and accompanying stent delivery balloon catheter system. In the same year, we further expanded our product line to include angioplasty balloons and catheters.

Most recently, we made our entry into the US$6b global drug-eluting stent market with the introduction of our flagship BioMatrix® and Axxion™ product lines. We have received CE Mark regulatory approval for Axxion in July 2005, and have submitted our BioMatrix drug-eluting stent for CE Mark regulatory approval.

Biosensors' affiliated companies maintain offices in Newport Beach, California, The Netherlands, Germany, Switzerland, Singapore, and Japan. Our interventional products are currently being manufactured in Singapore and The Netherlands.

Biosensors' BioMatrix drug-eluting stent is unique in that it uses a proprietary biodegradable polymer and anti-restenotic drug, Biolimus A9®. Our Axxion drug-eluting stent is a polymer-free system in which the drug is directly coated on the stent over a layer of glycocalix, a substrate designed to improve biocompatibility of the metal stent surface after the drug is released.

At international conferences around the world, leading cardiologists have highlighted the need for a safer drug-eluting stent with a shorter duration of polymer exposure in the body and the use of less toxic drugs which promote rather than delay the healing process. Cardiologists have commented that BioMatrix and Axxion drug-eluting stent which have no polymer remaining in the body after the drug elution is complete offer good alternatives to currently-available drug-eluting stent.

We have also licensed aspects of our proprietary drug-eluting stent technology to third parties, including Terumo Corporation, Guidant Corporation and specialty-stent providers, Devax, Inc. and Xtent, Inc.

Historical Price Data
 Date Open High Low Close
02 Jan 2008 0.900 0.970 0.900 0.900
31 Dec 2007 0.895 0.905 0.885 0.905
28 Dec 2007 0.870 0.910 0.865 0.895
27 Dec 2007
26 Dec 2007 0.850 0.860 0.825 0.850

Historial EPS ($) a
Rolling EPS ($) e
NAV ($) b
Historical PE
Rolling PE f
Price / NAV b
Dividend ($) d
52 Weeks High
Par Value ($)
Dividend Yield (%) d
52 Weeks Low
Market Cap (M)
Issued & Paid-up Units c
a Based on latest Full Year Results Announcement
b Based on latest Results Announcement (Full Year, Half Year or Interim)
c Rounded to the nearest thousand. Updated on 13/11/2007. Please click here for more information.
d Dividend is based on latest Full Year results announcement and excludes special dividend.
e Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
f Based on rolling EPS

12 Nov 2007 Biosensors Announces Second Quarter And Half Year Financial Results of Fiscal Year 2008
29 Oct 2007 Highlights Of Biosensors' Drug-Eluting Stent Technology Presented At Transcatheter Cardiovascular Therapeutics Convention
22 Oct 2007 CREATE Clinical Trial Results Demonstrates Excellent Efficacy And Safety Results For Excel Drug-Eluting Stent
22 Oct 2007 BioMatrix® Clinical Trial Data Continues To Demonstrate Outstanding Long-Term Safety And Efficacy Record
22 Oct 2007 Biosensors Acquires The Distribution Network Of Leading Indonesian Medical Distributor PT Fondaco Mitratama

Disclaimer: Although every reasonable care has been taken to ensure the accuracy and objectivity of the information contained in this publication, neither the publishers, authors and their employees and agents can be held liable for any errors, inaccuracies and/or omissions, howsoever caused. We shall not be liable for any actions taken based on the views expressed, or information provided within this publication. Information within this publication should not be taken or construed as an offer of, or the giving of, advice to buy or sell securities. The publishers, its associated companies and their officers, directors, employees may own or may have owned or have positions in the securities mentioned or reported in this publication, and may from time to time, add on to or dispose such securities. You should always seek your own professional advice from the appropriate advisor or institution. No part of this publication may be reproduced, stored, transmitted in any form of by any means without the permission of the Publisher.
ShareInvestor Pte Ltd 158 Cecil Street #08-03 Dapenso Building S(069545)
Tel: 62208807 Email: admin@shareinvestor.com